000			01445nam a2200229 4500
003			PC5774
005			20180417112608.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aAndrés Belmonte, Amado _91321 _eNefrología
245	0	0	_amTOR inhibitor–associated proteinuria in kidney transplant recipients. _h[artículo]
260			_bTransplantation Reviews, _c2012
300			_a26(1):27-9.
500			_aFormato Vancouver: Diekmann F, Andrés A, Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando). 2012 Jan;26(1):27-9.
501			_aPMID: 22137729
504			_aContiene 26 referencias
520			_aThe use of mammalian target of rapamycin inhibitor (mTOR-I) after kidney transplantation has been associated with a higher incidence of proteinuria compared with calcineurin inhibitors (CNIs). This review will focus on mTOR-I-associated proteinuria in different settings after kidney transplantation: de novo mTOR-I treatment in combination with CNI, de novo mTOR-I-containing and CNI-free treatment, early conversion from a CNI-based regimen to an mTOR-I-based regimen, and late conversion. Some possible mechanisms of mTOR-I-induced proteinuria will also be reviewed.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/5/pc5774.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c5774 _d5774